Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Auteurs

Francois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, Agnès-Paule Guerci-Bresler, Frédéric Maloisel, Delphine Rea, Valérie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff, Eric Jourdan, Marc Berger, Loïc Fouillard, Magda Alexis, Laurence Legros, Philippe Rousselot, Alain Delmer, Pascal Lenain, Martine Escoffre Barbe, Emmanuel Gyan, Claude-Eric Bulabois, Viviane Dubruille, Bertrand Joly, Bertrand Pollet, Pascale Cony-Makhoul, Hyacinthe Johnson-Ansah, Melanie Mercier, Denis Caillot, Aude Charbonnier, Jean-Jacques Kiladjian, Jacques Chapiro, Amélie Penot, Véronique Dorvaux, Iona Vaida, Alberto Santagostino, Lydia Roy, Hacene Zerazhi, Eric Deconinck, Herve Maisonneuve, Isabelle Plantier, Delphine Lebon, Yazid Arkam, Nathalie Cambier, Kamel Ghomari, Jean-Michel Miclea, Sylvie Glaisner, Jean-Michel Cayuela, Jean-Claude Chomel, Marc Muller, Ludovic Lhermitte, Marc Delord, Claude Preudhomme, Gabriel Etienne, François-Xavier Mahon, Franck- Emmanuel Nicolini, Francois Guilhot, Francoise Rigal-Huguet, Joëlle Guilhot, Agnès-Paule Guerci-Bresler, Delphine Rea, Valérie Coiteux, Martine Gardembas, Anne Vekhoff, Marc Berger, Laurence Legros, Philippe Rousselot, Pascal Lenain, Martine Escoffre Barbe, Viviane Dubruille, Pascale Cony-Makhoul, Hyacinthe Johnson-Ansah, Melanie Mercier, Charbonnier Aude, Lydia Roy, Nathalie Cambier, Jean-Michel Cayuela, Jean-Claude Chomel, Marc Delord, Claude Preudhomme, Gabriel Etienne, François-Xavier Mahon, Franck-Emmanuel Nicolini,